Cynata Therapeutics Limited · ASX:CYP
Cynata Therapeutics — Shareholder Meeting (November 2017)
21 slides from Cynata Therapeutics's shareholder meeting presentation, Nov 17, 2017
Slide 1: A Next Generation Stem Cell Company
For personal use only A Next Generation Stem Cell Company Cynata Therapeutics Limited (ASX:CYP) AGM – 2017
Slide 2: Important Information
Important Information This presentation has been prepared by Cynata Therapeutics Limited. (“Cynata” or the “Company”) based on information available to it as at the date of this presentation. The information in this presentation is provided in summary form and does not contain all information necess
Slide 3: A Year in Review: Key Milestones
A Year in Review Key Milestones For personal use only Strategic $6m Placement Commenced License option Strong GvHD Additional Partnership and to institutional world first agreement with pre-clinical data target $4m Placement investors clinical trial for FUJIFILM for and progress indications with FUJ
Slide 4: Our Technology – Revolutionising Stem Cell Therapy
Our Technology – Revolutionising Stem Cell Therapy Cynata’s proprietary CymerusTM technology facilitates commercial-scale manufacture of a consistent, robust and premier grade therapeutic mesenchymal stem cell (MSC) For personal use only product The Cymerus platform uses induced pluripotent stem cel
Slide 5: Why is stem cell therapy important and why do we use MSCs?
Why is stem cell therapy important and why do we use MSCs? For personal use only 1 2 3 4 5 MSCs are Potential to MSCs play a key immunosuppressive ~650* clinical trials specialised regenerate role in modulating and investigating the stem cells that and repair inflammation and co- immunoregulatory ef
Slide 6: Regenerative Medicine is a Rapidly Expanding Sector
Regenerative Medicine is a Rapidly Expanding Sector and Cynata is Positioned at the Forefront For personal use only Regenerative medicine market worth $18.9 billion globally in 2016 and expected to grow to over $53.7 billion by 20211 Sources: 1. Research and Markets - Global Regenerative Medicine Ma
Slide 7: GvHD – Represents a Significant and Growing Market
GvHD – Represents a Significant and Growing Market For personal use only • GvHD is a potentially fatal complication that can occur after a bone marrow transplant when the donor’s immune cells attack the host (patient). • Transplant market is expected to be worth +USD50 Billion by 20251 • +120,000 tr
Slide 8: World First Clinical Trial Underway
World First Clinical Trial Underway • World-first Phase I clinical trial commenced in graft-versus-host For personal use only disease (GvHD) • Global industry focus on Cynata’s progress • 7 sites now recruiting patients in the UK and Australia at major cancer treatment centers • 8 patients now dosed
Slide 9: Diverse Development Pipeline
Diverse Development Pipeline MSCs have broad therapeutic potential and Cynata is focussing on several exciting opportunities Pre-Clinical Phase 1 Evidence For personal use only University of Pre-clinical research with University of Massachusetts shown Cymerus MSCs to be Massachusetts highly effectiv
Slide 10: Other Disease Target Areas – Our Markets
Other Disease Target Areas – Our Markets Significant markets with a real opportunity to use regenerative medicine to improve For personal use only the lives of millions of people globally Heart Attack – Over Asthma- affects 1 in Acute Respiratory Brain Cancer / The Critical Limb 50,000+ Australian’s
Slide 11: ARDS Preclinical Study In Progress
ARDS Preclinical Study In Progress For personal use only The Study • Evaluating the effectiveness of Cymerus MSCs in sheep with Acute Respiratory Distress Syndrome (ARDS) • In partnership with the Critical Care Research Group in association with the Prince Charles Hospital in Brisbane. About ARDS •
Slide 12: Positive Preclinical Data in Asthma Studies
Positive Preclinical Data in Asthma Studies i.v. and intranasal delivery of Cymerus MSCs in well-established For personal use only • Study #1 chronic allergic airways disease model of asthma at Monash University: successfully completed Study #2 • Second study in asthma model at Monash involving Cyme
Slide 13: Positive Preclinical Data in Heart Attack
Positive Preclinical Data in Heart Attack For personal use only The Study • Preliminary study of the impact of Cymerus MSCs for heart attack conducted in an experimental rat model at the Westmead Institute for Medical Research Study Results • Early results show Cynata’s MSCs have the potential to re
Slide 14: Positive Preclinical Data in Critical Limb Ischemia
Positive Preclinical Data in Critical Limb Ischemia For personal use only The Study • Study at University of Wisconsin School of Medicine and Public Health, investigating the potential of Cymerus MSCs to treat critical limb ischemia (CLI) in mice. About Critical Limb • CLI is a disease caused by poo
Slide 15: Progress in the US and Canada
Progress in the US and Canada For personal use only • Received advice from the FDA Office of Cell, Tissue and Gene Therapy Products regarding the regulatory approval path for Cynata’s CYP-001 product (for the treatment of GvHD) in the US. – Cymerus MSC products are expected to be of suitable quality
Slide 16: Licensing Driven Business Model Driving Early Revenue Streams
Licensing Driven Business Model Driving Early Revenue Streams For personal use only Focus on developing early License option agreement signed with FUJIFILM for revenue streams through: the commercialisation of Cynata’s MSCs for GvHD • Exercise any time up to 90 days after Upfront Option/License paym
Slide 17: Cells as medicines - no longer a futurist therapy
Cells as medicines - no longer a futurist therapy August: FDA approved Novartis’ product, Kymriah, a CAR-T cell treatment for leukemia For personal use only August: Gilead to acquire Kite Pharma for US$11.9b. Kite develops CAR-T cell products for cancer treatment October: FDA approved Kite Pharma’s
Slide 18: What to Expect in FY18
What to Expect in FY18 For personal use only • Completion of the Phase 1 clinical trial of CYP-001 in GvHD • Progress in the Fujifilm strategic alliance • Completion of pre-clinical programs in asthma, heart attack, glioblastoma • Further development in apceth partnership • Further corporate partner
Slide 19: Investment Highlights Summary
Investment Highlights Summary Scalable, robust technology: Cymerus platform enables mass-production of therapeutic MSCs with For personal use only multiple clinical targets Clinical trials: World first Phase I clinical trial underway in GvHD; Cohort A fully enrolled Licensing-driven business m
Slide 20: Expert Team
Expert Team Dr Paul Wotton – Chairman • Former CEO of Ocata Therapeutics (NASDAQ: OCAT) managing it through a take-over by Astellas Pharma, in a US$379 million transaction. For personal use only • Previous executive roles with Antares Pharma Inc. (NASDAQ: ATRS), Topigen Pharmaceuticals and SkyePharm
Slide 21: Thank you for your attention
For personal use only Thank you for your attention Cynata Therapeutics Limited Contact details: Level 3 ross.macdonald@cynata.com 62 Lygon Street Carlton +61 (0) 412 119343 Victoria 3053 www.cynata.com Australia 16 November, 2017 www.cynata.com 21
Cynata Therapeutics — Shareholder Meeting (November 2017) on 6ix